



Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
12 September 2026 :: Issue 860

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director, Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

RSV

WHO prequalifies multi-dose RSV vaccine vial, paving the way to protecting more infants globally

9 September 2026 *Departmental update*

The World Health Organization (WHO) has prequalified the multi-dose vial presentation of the maternal respiratory syncytial virus (RSV) vaccine, RSVpreF (ABRYSVO®), marking **a major step toward protecting more infants from severe respiratory illness and pneumonia globally. The new presentation is expected to make maternal RSV vaccination more affordable and easier to deliver, particularly in countries supported by Gavi, the Vaccine Alliance.**

The decision builds on WHO's prequalification of the vaccine's single-dose presentation in March 2025 and Gavi's subsequent decision in July 2025 to establish a maternal RSV vaccine programme. This is aimed at protecting newborns and young infants from one of the leading causes of respiratory illness and hospitalization worldwide.

Each year, RSV is estimated to cause more than 3.6 million hospitalizations and approximately 100 000 deaths among children under 5 years of age. Almost half of these deaths occur in infants younger than 6 months of age, the population protected through maternal immunization. Roughly 97% of RSV deaths occur in low- and middle-income countries where there is limited access to supportive medical care. In many cases, children die at home before reaching a health facility.

Developed with support from the Gates Foundation, the lower-cost multi-dose vial presentation of the maternal RSV vaccine will improve the feasibility of countries to plan and deliver large-scale introductions of the vaccine into their national immunization programmes...

Gavi welcomes prequalification of multi-dose RSV maternal vaccine to protect infants

9 September 2026

:: WHO prequalification of a multi-dose RSV maternal vaccine marks a major step towards protecting newborns and infants from one of the leading causes of severe respiratory illness, hospitalisation and death worldwide.

:: The new vaccine is expected to reach women during pregnancy through routine maternal immunisation programmes in lower-income countries, where more than 97% of RSV-related child deaths occur.

:: The milestone strengthens the pathway towards Gavi-supported introduction, helping bring equitable access to life-saving RSV prevention closer for millions of families and children most at risk.

Geneva, 9 September 2026 – Gavi, the Vaccine Alliance welcomes the World Health Organization's (WHO) prequalification of a multi-dose vial presentation of an RSV maternal vaccine, a significant milestone, that paves the way for introduction of this new protective vaccine in lower income countries, with Gavi support...

.....
.....

.....

Ebola – Bundibugyo virus disease (BVD) – PHEIC/PHECS

WHO

WHO - Emergency situation reports

[10 September 2026 | Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo](#)

WHO - Emergency situation reports

Situation at a glance

Since the last Disease Outbreak News was published on 28 August 2026, the Bundibugyo virus outbreak in the Democratic Republic of the Congo has expanded to one additional health zone, Kayna, in North Kivu. This increase brings the total number of affected health zones to 61 across six out of 26 provinces of the country: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. As of 7 September 2026, the Democratic Republic of the Congo has reported 6757 confirmed cases, including 3267 deaths, resulting in a crude case fatality ratio (CFR) of 48.3%. The transmission dynamics remain variable across affected locations, with evidence of ongoing geographical expansion and sustained increase in cases in some health zones. The continuously high CFR highlights the seriousness of the disease and persistent challenges in timely case detection, access to early and adequate patient care, and effective interruption of transmission. Delayed detection of cases continues to increase the risk of further spread within households, communities, and healthcare setting...

WHO risk assessment

On 14 August 2026, WHO reassessed the risk of the outbreak of BVD, incorporating newly available information on the evolving situation. The risk for countries sharing land borders with the Democratic Republic of the Congo was separated from the risk for other countries in the African Region. The risk in the Democratic Republic of the Congo was assessed as very high, the risk for countries sharing land borders with the Democratic Republic of the Congo was again assessed as high, and the risks for the rest of the African region and at the global level was again assessed as low.

.....

Africa

Africa CDC welcomes increased UK support to Ebola response

Statement 6 September 2026

Africa CDC welcomes the United Kingdom Government's decision to increase its support to the Ebola response in the Democratic Republic of the Congo, bringing its total commitment to £78.7 million.

The announcement follows a meeting in Addis Ababa last week between H.E. Dr Jean Kaseya, Director General of Africa CDC, and UK Minister for Development Kirsty McNeill. Their discussions focused on the Ebola response, regional coordination and the need for sustained support to affected countries...

.....

INGOs

No new digest content identified.

.....

.....

.....

Polio – PHEIC

Polio this week [09 Sep 2026]

Headlines [Selected]

:: Containment Advisory Group Clarifies Containment Requirements for Polio Virus-Like Particles (VLP)

At its recent June 2026 meeting, the Containment Advisory Group (CAG) reviewed the application of poliovirus containment requirements to Polio Virus-Like Particles (VLPs) and related laboratory activities. Following expert deliberations, the CAG concluded that polio VLPs, as non-infectious and non-replicating particles that do not contain poliovirus RNA, are not subject to poliovirus containment requirements.

The CAG also clarified that containment requirements apply only when manufacturers or laboratories perform neutralization testing using live poliovirus, in accordance with the containment measures appropriate to the type of virus handled. Testing based on pseudoviruses does not fall within the scope of containment requirements.

This clarification provides important guidance to vaccine developers, manufacturers, laboratories, and National Authorities for Containment, supporting consistent implementation of the Global Action Plan for Poliovirus Containment while fostering innovation in polio vaccine research and development.

Summary of new polioviruses this week:

- :: Afghanistan : four WPV1 cases
- :: Pakistan: three WPV1-positive environmental samples
- :: DR Congo : five cVDPV2 cases
- :: Madagascar : one cVDPV1-positive environmental sample
- :: Nigeria : one cVDPV2 case
- :: Somalia : one cVDPV2-positive environmental sample

.....
.....

Featured Journal Content

Lancet Infectious Diseases

Sep 2026 Volume 26 Number 9 p871-974, e321-e385

Comment

[Beyond vaccines: closing the critical gap in diagnostics and therapeutics for outbreak response](#)

Tedros Adhanom Ghebreyesus, Jean Kaseya, Chikwe Ihekweazu, Vasee Moorthy, Mosoka Fallah, Shanelle Hall, Sylvie Briand

The ongoing Bundibugyo virus outbreak has exposed a major gap in the global outbreak response toolbox. Despite substantial advances in preparedness since the 2014–16 West Africa Ebola epidemic, the world still lacks reliable access to the diagnostics and therapeutics needed to rapidly respond to emerging infectious diseases. Although substantial attention and investment have been directed towards vaccine deployment and development, the Bundibugyo virus outbreak serves as a reminder that diagnostics and treatments are equally essential components of an effective response.

Vaccines have rightly been prioritised over the past decade, and much progress has been made in their development. Preventing disease is generally preferable to treating it, and vaccines often provide a cost effective and sustainable means of reducing disease burden. In addition, the Ebola

vaccine used for ring vaccination has proven to be a valuable tool for containing outbreaks. However, during the first weeks or months of an outbreak, vaccines might not yet exist, might not be available in sufficient quantities, or might not be deployable rapidly enough.

During the early phase of an outbreak, the immediate priorities are to mitigate the health impact, protect the health system, reduce transmission, and build trust in the response in affected communities. Effective therapeutics can dramatically reduce mortality and morbidity, thus protecting health-care systems and the health workforce until a vaccine comes. Post-exposure prophylaxis (PEP) has the potential to protect contacts at high risk and help break transmission chains. PEP increase the acceptance of and compliance to contact tracing. In many outbreak settings, these interventions can also contribute to building trust. Communities are more likely to seek care, cooperate with response efforts, and participate in surveillance activities when meaningful treatment options are available.

Over the past decade, an impressive architecture has emerged to support vaccine development, evaluation, procurement, and deployment.^{1–3} Public, philanthropic, and multilateral actors have created pathways that reduce commercial uncertainty and provide manufacturers with confidence that successful products will have a viable route to market. This model, with important roles for the Coalition for Epidemic Preparedness Innovations, the WHO R&D Blueprint for Epidemics, and GAVI, the Vaccine Alliance, has strengthened global preparedness. **No equivalent ecosystem exists for therapeutics and diagnostics.**

This gap reflects a deeper tension between public health objectives and commercial incentives. From a public health perspective, the goal is straightforward: reduce mortality, reduce transmission, and mitigate the societal and economic consequences of outbreaks. Manufacturers, however, operate under different constraints, as they must manage commercial risk, recover development costs, secure sustainable production, and generate sufficient returns to justify investment. For products targeting sporadic outbreaks of diseases affecting primarily low-income countries, these incentives are often weak.

The result is a persistent failure to translate promising scientific advances into accessible interventions. Candidate therapeutics can be successfully developed, evaluated, and even licensed, and yet remain unavailable at scale. An example is the Ebola monoclonal antibody Ebanga, which is not licensed by regulatory authorities in African countries despite being proven safe and effective in a high-quality clinical trial conducted in DR Congo⁴ and then licensed by the US Food & Drug Administration (FDA). Diagnostic platforms face similar challenges. The market signals needed to sustain manufacturing capacity and stockpiles are often absent, leaving affected countries dependent on ad hoc arrangements when emergencies occur.

The WHO R&D Blueprint for Epidemics was established in the aftermath of the West Africa Ebola epidemic to help address these market failures and accelerate the development of medical countermeasures for epidemic-prone diseases. The Blueprint has contributed significantly to the prioritisation and evaluation of vaccines and has helped coordinate global research efforts during public health emergencies.

African institutions are building the regional architecture needed to ensure that vaccines, diagnostics, and therapeutics reach patients more rapidly during outbreaks. The Africa Centres for Disease Control and Prevention (Africa CDC) has established mechanisms to identify continental priorities, coordinate continental clinical research, support African manufacturing, and develop pooled procurement to create sustainable markets. Recognising the need for stronger governance of diagnostic innovation, Africa CDC established the Diagnostic Advisory Committee (DAC) to accelerate access to diagnostics on the continent. DAC represents an important regional complement to global research and development coordination. These initiatives complement WHO's global normative role.

The challenge now is to systematically extend a vision beyond vaccines and develop equally robust mechanisms for therapeutics and diagnostics.

Several therapeutic approaches show considerable promise for both treatment and post-exposure prophylaxis. Small-molecule antivirals could offer scalable and potentially lower-cost options for some diseases. Monoclonal antibodies have shown remarkable efficacy against pathogens, such as Ebola virus, and continue to benefit from rapid advances in discovery and manufacturing technologies.

To realise these promises, a dedicated ecosystem for diagnostics and therapeutics that mirrors the strengths of the vaccine ecosystem while recognising the distinct characteristics of these products [is needed?]. The research and development blueprint already supports priority setting and research and development partner coordination at the global level, whereas Africa CDC's convening leadership does so at the continental level. Such an ecosystem should fill in the gaps on support for clinical evaluation, manufacturing at risk, stockpiling where appropriate, advance purchase commitments, and rapid deployment during emergencies. The ecosystem should be designed explicitly to align commercial incentives with public health objectives and ensure that populations contributing to research benefit from its outcomes.

The required investments are modest when compared with the human, economic, and political costs of uncontrolled outbreaks. More importantly, these investments would help ensure that scientific progress translates into tangible public health impact.

The lesson from Bundibugyo virus is clear. Effective outbreak response requires diagnostics that identify infections rapidly, treatments that reduce mortality, and prophylactic interventions that help interrupt transmission. No single intervention will be sufficient in every scenario. The more tools available in our toolbox, the better prepared the world will be to respond to the next outbreak.

The next generation of preparedness requires an equally ambitious ecosystem for diagnostics and therapeutics—one that connects global scientific leadership with strong regional institutions. WHO's R&D Blueprint for Epidemics, Africa CDC's DAC, the Continental Research Agenda, regional manufacturing initiatives, the African Pooled Procurement Mechanism, and strengthened regulatory systems each address crucial components of this pathway. The challenge now is to integrate them into a coherent ecosystem that takes innovation from discovery to equitable access. Outside Africa, mechanisms are needed to enable access regardless of where communities live. The next outbreak should not find the world repeating the same mistakes.

Comment

[Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak](#)
Krutika Kuppalli, et al.

The ongoing 2026 Bundibugyo virus disease (BVD) public health emergency of international concern in DR Congo and Uganda has exposed gaps in preparedness for non-zairene orthoebolaviruses. With BVD vaccines months away, attention has turned to experimental, immunological, epidemiological, and operational evidence supporting the rVSVΔG-ZEBOV-GP vaccine (Ervebo) for potential cross-protection. We believe the available evidence warrants reconsideration of its use in carefully selected high-risk populations while prospectively evaluating its effectiveness against Bundibugyo virus (BDBV)...

.....
.....

PATH – Jeremy Farrar

[PATH appoints Dr. Jeremy Farrar as Chief of Asia, Middle East, and Europe regional division](#)

September 9, 2026 by PATH

Geneva, Switzerland—PATH is pleased to announce the appointment of Dr. Jeremy Farrar, a globally recognized leader in public health and clinical medicine, as Chief of its Asia, Middle East, and Europe regional division. **In this role, Dr. Farrar will join PATH's Executive Leadership Team and oversee the organization's work across a dynamic and critical set of regions central to advancing global health. He will join the organization on October 1 and be based in Geneva.**

Dr. Farrar brings decades of experience at the forefront of global health, including leadership roles as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Vietnam, Assistant Director-General at the World Health Organization (WHO), and Director of Wellcome. Throughout his career, he has led transformative efforts at the intersection of clinical research, public health, and innovation. His work has spanned infectious diseases, noncommunicable diseases, emerging health threats, pandemic preparedness, workforce development, and health systems strengthening to address some of the world's most pressing health challenges.

At PATH, Dr. Farrar will lead the organization's work across Asia, the Middle East, and Europe, deepening partnerships with local communities, governments, multilateral organizations, academic institutions, private-sector organizations, and philanthropic partners to advance sustainable health solutions. He will work closely with PATH's country and regional teams to support locally driven priorities and strengthen collaboration across the region.

"Joining PATH at this moment is a very exciting opportunity," said **Dr. Farrar. "For nearly 50 years, PATH has been recognized for bringing scientific excellence to some of the most complex health challenges facing communities that have too often been overlooked. This is a pivotal moment for global health, and an important moment to sharpen how innovation is translated into public health impact.** Doing so will require us to address today's challenges with both urgency and ambition, anticipating and preparing for future changes in national and global health, and ensuring broader access to science and innovation. I look forward to contributing to that effort."...

.....
.....

Health Ethics Guidance

[Developing health ethics guidance: a systematic approach](#)

World Health Organization (2026) License: CC BY-NC-SA 3.0 IGO PDF: [9789240121867-eng.pdf](#) (779.92 KB)

Abstract

This publication provides a systematic methodology for the development of health ethics guidance documents (HEGDs), **addressing the need for a formal, transparent and evidence-informed approach to the formulation of normative health ethics guidance.** Developed within the context of WHO's normative and standard-setting functions, it **offers a structured framework to support organizations and experts involved in preparing ethics guidance for health care, research and public health policy.**

The publication examines the historical foundations of health ethics guidance, the relationship between empirical evidence and ethical reasoning, and the role of WHO in promoting high-quality, ethically grounded normative instruments.

The document presents a step-by-step process for developing HEGDs, covering scope definition, formulation of key questions, evidence gathering and appraisal, development of normative

statements, stakeholder engagement, drafting, peer review, monitoring and evaluation. **It emphasizes methodological rigour, transparency, inclusiveness, critical appraisal of evidence and ethical arguments, and explicit justification** of normative recommendations.

Accompanied by a practical toolkit including checklists, appraisal frameworks, literature review resources and a glossary, the publication aims to strengthen the quality, consistency and credibility of health ethics guidance while supporting its adaptation to diverse health systems and policy contexts.

[Excerpt]

Key principles of the systematic approach

The systematic approach described in this publication is based upon the following key principles:

Methodological rigour. The development of HEGDs must be grounded in a clearly defined, structured and transparent methodology that ensures consistency, credibility and accountability. This entails not only following a step-by-step process but also applying critical appraisal tools, adhering to ethical reasoning standards and documenting each phase of development with precision. Methodological rigour safeguards against arbitrariness, supports the legitimacy of normative statements, and ensures that ethical guidance is robust, reproducible and responsive to evolving health challenges across diverse settings.

Openness to a broad variety of evidence types. Preparing HEGDs requires a broad and inclusive understanding of “evidence” that recognizes the diverse sources that support normative statements and deliberately moves beyond the traditional dependence on empirical data typical of clinical guideline development. This approach underscores the importance of integrating both qualitative and quantitative methodologies, acknowledging the interdisciplinary complexity of health care, and incorporating multiple perspectives to effectively justify and support the normative content of HEGDs.

Transparency and accountability. It is necessary to document the HEGD development process, including evidence sources, stakeholder inputs and decision-making rationales. Making certain that all methodological choices are explicit enhances confidence in the normative statements presented.

Critical appraisal of evidence and ethical arguments. The development of HEGDs must incorporate systematic mechanisms to evaluate the quality, relevance, trustworthiness and applicability of the evidence that underpins their normative statements. In addition, the critical appraisal of empirical literature should be paired with rigorous and detailed analysis of ethical arguments, ensuring that both evidence and reasoning meet high standards of scrutiny.

Clear justification and rationale for the normative statements. To ensure transparency, ethical guidance must clearly disclose its normative foundations. This publication advocates the explicit articulation of the principles, values and ethical theories that support HEGDs, along with a well-defined rationale for each specific normative statement.

Effective stakeholder engagement. Ethics guidance cannot be developed in isolation. This publication emphasizes the importance of inclusive stakeholder engagement, ensuring that HEGDs incorporate diverse perspectives, especially those of target audiences and potential end users, end beneficiaries, individuals from low- and middle-income countries, and vulnerable populations. Such participation is essential not only for ensuring broad applicability, but also for legitimacy and for identifying and addressing potential challenges, unintended impacts and conflicting interests that may arise during the implementation of HEGDs.

Adaptability and context sensitivity. Developers should tailor HEGDs to diverse health systems while maintaining consistency with a formal, standardized approach. Ethical guidance should be sufficiently flexible to accommodate varying regulatory, sociocultural and economic conditions.

.....
.....

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

.....
.....

WHO & Regional Offices [12 Sep 2026]

<https://www.who.int/news>

Selected News/Announcements/Statements

9 September 2026 *Departmental update*

[WHO prequalifies multi-dose RSV vaccine vial, paving the way to protecting more infants globally](#)

9 September 2026 *News release*

[Dr Vanessa Kerry appointed to new role as WHO Director-General's Special Envoy for Health Resilience](#)

The World Health Organization has appointed Dr Vanessa Kerry as the WHO Director-General's Special Envoy for Health Resilience. Building on her previous role as WHO's first Director-General Special Envoy for Climate Change and Health, Dr Kerry will help advance a broader agenda focused on building resilient, integrated and sustainably financed health systems capable of responding to day-to-day challenges and emerging threats from climate change, health emergencies and other complex global challenges.

In her new role, Dr Kerry will engage with governments, development partners, multilateral institutions, civil society and the private sector to advocate for stronger health systems, more sustainable financing approaches, and stronger coordination and alignment of partners and resources behind national priorities...

9 September 2026 *Departmental update*

[Public health leaders explore how traditional medicine can support health system transformation](#)

Traditional medicine researchers, policymakers and public health experts recently gathered in Cape Town, South Africa, at the World Congress on Public Health (WCPH). The workshop examined the contribution of traditional medicine to public health through the implementation of the recently adopted WHO Global Traditional Medicine Strategy 2025–2034. The session, Traditional Medicine and Public Health: Preparing for System-Wide Change, highlighted the growing role of traditional, complementary and integrative medicine (TCIM) in advancing evidence-informed, people-centred care...

.....

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

9 September 2026 *Departmental update*

[WHO prequalifies multi-dose RSV vaccine vial, paving the way to protecting more infants globally](#)

:::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 7 September 2026 | *Feature Story*

[Regional Health Data Hub: WHO's initiative to strengthen informed health action](#)

WHO Region of the Americas PAHO

:: 10 Sep 2026

[One month after the Colombia earthquake, PAHO/WHO continues to support response and stabilization](#)

The Organization is supporting Colombia's health authorities to maintain essential services, strengthen disease surveillance and address the evolving health needs of affected communities. Bogotá, Colombia, 10 September 2026 (PAHO/WHO) - One month after a magnitude 7.4 earthquake struck western Colombia, the Pan American Health Organization /...

WHO South-East Asia Region SEARO

:: 10 September 2026 *News release*

[WHO South-East Asia Regional Committee session concludes with landmark decisions to advance equity and Health for All](#)

WHO European Region EURO

No new digest content identified

WHO Eastern Mediterranean Region EMRO

:: 10 September 2026

[Already under severe strain, Yemen's health system faces renewed conflict](#)

:: 7 September 2026

[WHO Representative visits Khartoum's damaged referral hospitals as the Government prepares to restore critical health services](#)

WHO Western Pacific Region

No new digest content identified.

:::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

:::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health

10 September 2026 | Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

4 September 2026, Vol. 101, No. 35

https://hq_weeklyepidemiologicalrecord.cmail19.com/t/d-l-wyuwud-ijjdtklujh-y/

[Reviewed earlier]

.....

New WHO Publications

<https://www.who.int/publications>

Selected

10 September 2026

WHO guidelines for malaria

Overview

The *WHO guidelines for malaria* bring together the Organization's most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.

Recommendations on malaria continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website.

This version of the Guidelines includes updated recommendations on: (i) intermittent preventive treatment in HIV-positive pregnant women; (ii) the use of single-dose primaquine for transmission blocking in areas of moderate to high malaria transmission; (iii) a new formulation of artemether-lumefantrine for treating malaria in children less than 5kg bw; and (iv) three-dose versus four-dose vaccination schedules in areas of perennial malaria transmission.

8 September 2026

User manual for the Quick and Immediate Risk Assessment (QIRA) algorithm for Member States

Overview

This user manual provides guidance on the application of the World Health Organization's Quick and Immediate Risk Assessment (QIRA) algorithm, a practical tool developed to support Member States in conducting rapid assessments of acute public health events within routine public health intelligence activities. Using an all-hazards approach, the manual explains how to apply the algorithm step by step to determine the immediate level of risk associated with verified signals or events and to identify appropriate initial response actions. It describes the algorithm's structure, including its domains, risk classification, predefined actions, confidence assessment and documentation requirements, and clarifies its relationship with other WHO risk assessment tools and the International Health Regulations (2005).

8 September 2026

User manual for the Member State Rapid Risk Assessment (MS-RRA) tool

.....

.....

.....

Africa

Africa CDC [12 Sep 2026]

<https://africacdc.org/>

News & Updates [Selected]

Press Release

[Emergency Funding Alone is Insufficient to End Bundibugyo virus](#)

8 September 2026

Communiqué

[Africa CDC extends condolences to President Samia Suluhu Hassan and the people of Tanzania](#)

7 September 2026

Press Releases

[Africa CDC and Geneva Learning Foundation Partner to Strengthen Immunisation](#)

7 September 2026

ADDIS ABABA and Geneva, 4 September 2026 – A new partnership between the Africa Centres for Disease Control and Prevention (Africa CDC) and the Geneva Learning Foundation (TGLF) aims to strengthen immunisation across Africa by connecting continental priorities with frontline health workers and bringing their experience and local solutions into decision-making.

The partnership will support implementation of the Continental Immunisation Strategy (CIS), launched in April 2026 at the World Health Summit Regional Meeting in Nairobi...

Statement

[Africa CDC welcomes increased UK support to Ebola response](#)

6 September 2026

Africa CDC welcomes the United Kingdom Government's decision to increase its support to the Ebola response in the Democratic Republic of the Congo, bringing its total commitment to £78.7 million.

The announcement follows a meeting in Addis Ababa last week between H.E. Dr Jean Kaseya, Director General of Africa CDC, and UK Minister for Development Kirsty McNeill. Their discussions focused on the Ebola response, regional coordination and the need for sustained support to affected countries...

African Medicines Agency [12 Sep 2026]

<https://au-ama.africa/news-events/>

Latest News & Events

No new digest content identified.

.....

.....

China – CDC+

National Health Commission of the People's Republic of China [12 Sep 2026]

<http://en.nhc.gov.cn/>

News

Website not responding at inquiry.

National Medical Products Administration – PRC [12 Sep 2026]

<https://english.nmpa.gov.cn/>

No new digest content identified..

China CDC

CCDC Weekly Reports: Current Volume (8)

<https://weekly.chinacdc.cn/article/current>

2026 Vol. 8 No. 37 [PDF](#)

No new digest content identified.

.....
.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

[**Seasonal surveillance of dengue in the EU/EEA**](#)

11 September 2026

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

.....
.....

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.

Indian Council of Medical Research (ICMR)

Press Releases

No new digest content identified.

Ministry of Health and Family Welfare

Press Releases

[**India Administers 80 Lakh HPV Vaccine Doses, Marking Major Milestone in Cervical Cancer Prevention**](#)

:: More than 8 Million HPV Vaccine Doses Administered Under National HPV Vaccination Campaign
:: Gujarat, Uttar Pradesh, Madhya Pradesh and Mizoram Achieve 100% Coverage; Bihar, Andhra Pradesh and Assam Cross 90%

:: Uttar Pradesh Leads with More than 22 Lakh Adolescent Girls Vaccinated

:: All Vaccination Sessions Conducted Under Medical Supervision with 24×7 Arrangements for Management of Rare AEFI

:: National HPV Vaccination Campaign Launched by Prime Minister Narendra Modi in February 2026 to Provide Free, Voluntary Single-Dose Vaccination to 14-Year-Old Girls

Posted On: 11 SEP 2026 2:12PM by PIB Delhi

India has crossed a significant milestone in its efforts to prevent cervical cancer, with more than 80 lakh (8 million) doses of Human Papillomavirus (HPV) vaccine administered under the National HPV Vaccination Campaign since its launch in February 2026. The milestone marks the expanding reach of HPV vaccination through the public health system and reinforces India's commitment to strengthening preventive healthcare for adolescent girls...

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+ White House

Presidential Actions – Executive Orders; Memoranda; Proclamations
No new digest content identified.

Department of State

Press Releases - Selected
No new digest content identified.

HHS

Press Room - Selected

HHS Announces Key Leadership Selections at FDA to Promote Innovation, Reform, and National Health Priorities

WASHINGTON, D.C. — September 8, 2026 — The U.S. Department of Health and Human Services today announced the selection of four senior leaders at the U.S. Food and Drug Administration (FDA), strengthening the agency's leadership team as FDA advances its public health pillars to deliver profound benefits for patients, consumers, and public health. These appointments reflect a deliberate strategy to drive innovation and meaningful reform across FDA, positioning the Agency to lead on its core priorities: advancing innovation and global leadership, strengthening national health security, increasing access to affordable medicines and medical products, and promoting health wellness for the American people.

:: Jared Seehafer, M.S. has been selected to serve as FDA's first Deputy Commissioner for Technology and Artificial Intelligence;

:: Michael Davis, M.D., Ph.D., has been selected as Director of the Center for Drug Evaluation and Research (CDER);

:: **Karim Mikhail, B.Pharm, MSc, has been selected as Director of the Center for Biologics Evaluation and Research (CBER); and**

:: Bret Koplow, Ph.D., J.D., has been selected as Director of the Center for Tobacco Products (CTP).

NIH [to 12 Sep 2026]

News Releases

Physician-scientist and informatics leader Dr. Peter Embí to helm NIH's National Library of Medicine

September 2, 2026 — He is anticipated to begin his role on Sept. 10, 2026.

FDA

Press Announcements

No new digest content identified.

FDA CBER

What's New for Biologics

No new digest content identified.

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

No future meeting dates posted.

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

[Pediatric Advisory Committee Meeting Announcement - 09/16/2026](#)

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

[CDC Statement on Increases in Recent Animal Rabies Activity and Associated Human Exposures](#)

Statement For immediate release: September 10, 2026

Today, the CDC issued a Health Alert Network (HAN) health advisory to inform clinicians, health departments, and the public about increases in recent animal rabies activity and associated human exposures. Rabies is preventable when people who have been exposed receive appropriate administration of the rabies vaccine before symptoms begin.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified [last updated August 7, 2024]

ACIP

[2026 Meetings Schedule](#) *[as posted]*

- March 18-19 (Due to ongoing litigation, this meeting is cancelled)
- June 24-26 (Due to ongoing litigation, this meeting is cancelled)
- October 21-23

National Vaccine Advisory Committee (NVAC)

<https://www.hhs.gov/programs/national-vaccine-program/nvac/index.html>

Upcoming Meetings/Latest Updates

No new meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV meetings – TBD

[Recharter for the Advisory Commission on Childhood Vaccines](#)

A Notice by the Health Resources and Services Administration on 07/21/2026

SUMMARY:

In accordance with the Federal Advisory Committee Act (FACA), the Department of Health and Human Services is hereby giving notice that the Advisory Commission on Childhood Vaccines (ACCV) has been rechartered. The effective date of the renewed charter is July 21,

2026. ... A copy of the ACCV charter is available on the ACCV website at <https://www.hrsa.gov/advisory-committees/vaccines/index.html>..

MMWR Weekly

<https://www.cdc.gov/mmwr/index2026.html>

September 10, 2026 / No. 35

[PDF of this issue](#)

:: [Notes from the Field: Clinical Characteristics of Patients with Ebola Disease Caused by Bundibugyo Virus — Uganda, 2026](#)

:: [Notes from the Field: Characteristics and Monitoring of the 2026 Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo, August 2026](#)

.....

National Science Foundation/NSF

[News](#)

No new digest content identified.

.....

U.S. Congress

House

No new digest content identified.

Senate

No new digest content identified.

.....

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

No new digest content identified.

.....

.....

.....

U.S. Medical, Scientific, Professional Societies; Health Organizations

This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 12 Sep 2026)

No new digest content identified.

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 12 Sep 2026)

News

American Academy of Pediatrics Offers Guidance on Managing Infants with Congenital Measles as Disease Outbreaks Rise

September 8, 2026

Measles is now rapidly spreading in some communities with low vaccination rates, putting newborns at risk

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 12 Sep 2026)

No new digest content identified.

America's Health Insurance Plans (AHIP)

<https://www.ahip.org/news>

(Accessed 12 Sep 2026)

News

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>

(Accessed 12 Sep 2026)

Recent Press Releases

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 12 Sep 2026)

Press Releases

No new digest content identified.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 12 Sep 2026)

Latest News

No new digest content identified.

American Public Health Association (APHA)

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc>

(Accessed 12 Sep 2026)

No new digest content identified.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 12 Sep 2026)

News

Transparency needed around ID/HIV research funding

Reports that the Administration plans to transfer funds that Congress has allocated to the National Institute of Allergy and Infectious Diseases for biopreparedness and biodefense to the Department of Defense raise significant concerns, particularly as part of a pattern of disruptions in funding and staffing at NIAID. The American people deserve to know how their tax dollars are being spent. Moreover, the federal government must ensure that infectious diseases research funding is spent as intended by Congress and not diverted from the principal entity charged with leading biomedical research in infectious diseases: NIAID. As recognized by Congress, this research is critical to protect Americans from infectious diseases, strengthen our biodefense capabilities, and secure our preparedness for outbreaks and pandemics.

IDSA recognizes that DOD has a strong history of conducting essential infectious diseases research that protects military personnel. IDSA has long supported collaborations between NIAID and DOD, particularly those focused on biodefense, and continues to do so with the appropriate transparency and guardrails. Effective biodefense research requires expertise across medicine, science, public health, technology, the military, economics and other relevant fields.

We call on the Administration to release a detailed accounting of how transferred funds will be used, what NIAID grants or programs are projected to lose funding because of the transfer, and a plan to ensure that ID and HIV research priorities are fully funded, including programs aimed at detecting and managing emerging infectious diseases, antimicrobial resistance, and clinical trial and research networks aimed at HIV/AIDS.

— Ronald G. Nahass, MD, MHCM, FIDSA – President, IDSA

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>

(Accessed 12 Sep 2026)

News and Updates

No new digest content identified.

National Medical Association (NMA)

<https://nmanet.org/blog/>

(Accessed 12 Sep 2026)

Latest News

No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)

<https://pids.org/news-announcements/>

(Accessed 12 Sep 2026)

News & Announcements

No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)

<https://shea-online.org/news/>

(Accessed 12 Sep 2026)

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 12 Sep 2026)

News

No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions [Selected]

.....

Kaiser Family Foundation/KFF [12 Sep 2026]

https://www.kff.org/search/?post_type=press-release

Research, Analysis

Mapping the Global Health Landscape: Analysis of Fourteen International Organizations

Sep 11, 2026 *Report*

Summary

Growing attention to health challenges, particularly those facing low- and middle-income countries, has led to the emergence of new global institutions over time, especially in the past twenty-five years. Today, the global health architecture includes a number of diverse international organizations with different mandates, governance models, financing structures, and operational approaches. At the same time, several of these organizations support the same countries, address similar health issues, and rely on the same set of revenue sources. As such, questions have been raised about whether there is duplication and/or opportunity for synergies and better coordination across entities. These questions have become even more acute as fiscal environments have increasingly tightened. As a result, multiple reform efforts have been launched to explore these questions. As one input into these processes, KFF has developed a descriptive mapping of 14 key global health and related international institutions, with a focus on their work to address health challenges in low- and middle-income countries. By looking across a range of variables, it is intended to inform discussions about synergies and coordination, duplication, comparative advantage, shared challenges, and architectural reform.

KFF Tracker: America First MOU Bilateral Global Health Agreements

Sep 11, 2026 *Tracker*

This tracker provides up-to-date information on [34] countries with signed bilateral MOU global health agreements with the U.S.

.....

Vaccine Integrity Project – CIDRAP [to 12 Sep 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

Announcements, Viewpoints

No new digest content identified.

.....

Center for Vaccine Ethics & Policy - GE2P2 Global Foundation [to 12 Sep 2026]

<https://centerforvaccineethicsandpolicy.net/>

No new digest content identified.

.....

Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>
No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)
:: [*WHO*](#)
:: [*Organization Announcements*](#)
:: [*Journal Watch*](#)
:: [*Pre-Print Servers*](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [12 Sep 2026]
<https://alleninstitute.org/news-press/>
No new digest content identified.

Gates Foundation [12 Sep 2026]
<https://www.gatesfoundation.org/ideas/media-center>
Press Releases & Statements
No new digest content identified.

CARB-X [12 Sep 2026]
<https://carb-x.org/>
News
No new digest content identified..

Chan Zuckerberg Initiative [12 Sep 2026]
<https://chanzuckerberg.com/newsroom/>
Newsroom
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [12 Sep 2026]
<http://cepi.net/>
News
News

[India ramps up Disease X preparedness with \\$8.9 million funding boost for its freezer-free RNA vaccine](#)

PUNE/OSLO, 9 SEP—Indian biotechnology company Immunoscrypt Life Science will receive up to US\$8.9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance clinical testing of its thermostable next-generation saRNA vaccine platform, marking an important boost to India's growing RNA medicine sector while potentially expanding the reach of RNA vaccines to communities where cold-chain infrastructure is limited...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 12 Sep 2026]

<https://cioms.ch/>

News; Publications; Events

[Reciprocal Effects of Drugs & the Microbiome – 2nd webinar](#)

Online - October 7, 2026 Webinar Time: 14:00 – 15:30 (UTC+2, CEST)

DARPA – Defense Advanced Research Projects Agency [U.S.] [12 Sep 2026]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [12 Sep 2026]

<https://dndi.org/press/press-releases/>

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [12 Sep 2026]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [12 Sep 2026]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [12 Sep 2026]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [12 Sep 2026]

<http://www.euvaccine.eu/>

News

No new digest content identified.

Fondation Merieux [12 Sep 2026]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [12 Sep 2026]

<https://www.gatesmri.org/news>

News: Articles and Publications

No new digest content identified.

Gavi [to 12 Sep 2026]

<https://www.gavi.org/>

News Releases, VaccinesWork

9 September 2026

[Gavi welcomes prequalification of multi-dose RSV maternal vaccine to protect infants](#)

8 September 2026

[Papua New Guinea launches HPV vaccination to protect girls from cervical cancer](#)

GE2P2 Global Foundation [12 Sep 2026]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements/Digests

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 04 Sep 2026 Issue 43](#)

GHIT Fund [12 Sep 2026]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 12 Sep 2026]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [12 Sep 2026]

<https://www.glopid-r.org/>

News & Event

No new digest content identified.

Hilleman Laboratories [12 Sep 2026]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [12 Sep 2026]

<https://www.hhmi.org/news>

News & Stories

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [12 Sep 2026]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [12 Sep 2026]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [12 Sep 2026]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 12 Sep 2026]

<https://www.ich.org/page/public-consultations>

News/Pubs/Press Releases [Selected]

No new digest content identified.

ICRC [to 12 Sep 2026]

<https://www.icrc.org/en/news>

Latest press releases and statements

Statement

08-09-2026

[ICRC president: Urgent steps needed to de-escalate hostilities in Middle East](#)

Geneva (ICRC) – The recent escalation of hostilities in the Middle East affecting Yemen and Saudi Arabia risks a further expansion of conflict in the region that, if not contained, could worsen the already devastating humanitarian situation faced by millions of people. Concrete steps must, at all times, be taken to protect civilians and essential infrastructure.

IFFIm [12 Sep 2026]

<http://www.iffim.org/>

Press Releases/Announcements
No new digest content identified.

IFRC [to 12 Sep 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

10/09/2026

Colombia: IFRC calls for sustained support to earthquake-affected communities, one month on

Press release 08/09/2026

Nepal floods: IFRC delivers safe water and health care to affected communities

IPPS - International Pandemic Preparedness Secretariat [12 Sep 2026]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [12 Sep 2026]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

InterAcademy Partnership (IAP)

<https://www.interacademies.org/news/press-releases>

News

No new digest content identified.

ISC / International Science Council [to 12 Sep 2026]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News, Blogs

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

No new digest content identified.

IVAC [12 Sep 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [12 Sep 2026]

<http://www.ivi.int/>

IVI News & Announcements

ECHO-M concludes after advancing sustainable cholera prevention and control in Mozambique

MAPUTO, Mozambique, August 2026 – In one of Mozambique’s most vulnerable cholera hotspots, 200,000 doses of oral cholera vaccine (OCV) were administered, and cholera and diarrheal disease surveillance systems were strengthened across five sentinel health facilities. The project also contributed to the development and roll-out of Mozambique’s National Cholera Plan (NCP), supporting the country’s long-term efforts to prevent and control cholera...

Johns Hopkins Center for Health Security [12 Sep 2026]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 12 Sep 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 12 Sep 2026]

<http://www.msf.org/>

Latest [Selected Announcements]

Yemen

As conflict engulfs Mocha, health workers keep hospital open

11 Sep 2026

Nepal

As communities in Nepal turn to recovery, immediate needs do not require MSF response

8 Sep 2026

Sudan

Aid cuts force mass clinic closures across Sudan, leaving millions without healthcare

8 Sep 2026

Chad

Sudanese refugees face the effects of humanitarian funding cuts in Ouré-Cassoni, Chad

7 Sep 2026

Refugees, IDPs and people on the move

MSF assists migrants in distress who disembarked on West African shores

7 Sep 2026

National Academy of Medicine - USA [to 12 Sep 2026]

<https://nam.edu/programs/>

News, Stories, Insights
No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM] - USA [to 12 Sep 2026]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

PATH [12 Sep 2026]

<https://www.path.org/media-center/>

Newsroom [Selected]

[PATH appoints Dr. Jeremy Farrar as Chief of Asia, Middle East, and Europe regional division](#)

September 9, 2026 by PATH

Rockefeller Foundation [to 12 Sep 2026]

<https://www.rockefellerfoundation.org/>

News and Announcements

[The Rockefeller Foundation and TPC Announce Strategic Collaboration to Advance New Models of Impact Across Asia](#)

Press Releases Published Date September 11, 2026

SINGAPORE | September 11, 2026 — The Rockefeller Foundation and TPC (Tsao Pao Chee), together with NO.17 Foundation, today announced a Memorandum of Understanding (MoU) to explore a strategic collaboration to address interconnected challenges across land, food, health and energy in Asia...

Sabin Vaccine Institute [12 Sep 2026]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [12 Sep 2026]

<http://www.unaids.org/en>

News, Stories, Updates

No new digest content identified.

UNICEF [to 12 Sep 2026]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

No new digest content identified.

Unitaid [12 Sep 2026]

<https://unitaid.org/>

News releases

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [12 Sep 2026]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified. [Last update Jun 30, 2023]

Vaccine Confidence Project [12 Sep 2026]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [12 Sep 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[**Vaccine Update Newsletter August 2026**](#)

Wellcome Trust [12 Sep 2026]

<https://wellcome.org/>

News. Opinion, Reports

No new digest announcements identified.

The Wistar Institute [to 12 Sep 2026]

<https://www.wistar.org/news/press-releases>

Press Releases

September 9, 2026

[**Wistar Institute Wins \\$15M+ NIH Investment to Advance HIV Cure Research Strategies**](#)

Grants funding positions Philadelphia as an anchor for HIV cure research—advancing combination strategies aimed at durable, drug-free remission.

World Bank [to 12 Sep 2026]

<http://www.worldbank.org/en/news/all>

News [Selected]

No new digest announcements identified.

WFPHA: World Federation of Public Health Associations [12 Sep 2026]

<https://www.wfpha.org/>

Blog, Events

[**HPV Vaccination Across the Life Course: Protecting More People from Preventable Cancer**](#)

Sep 7, 2026

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest announcements identified.

World Organisation for Animal Health [WOAH/OIE] [12 Sep 2026]

<https://www.oie.int/>

Latest News

No new digest announcements identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [12 Sep 2026]

<https://alliancerm.org/press-releases/>

Selected Press Releases

Press Releases

[ARM Statement on the Appointment of Karim Mikhail as the Director of the Center for Biologics Evaluation and Research](#)

BIO [12 Sep 2026]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [12 Sep 2026]

<http://www.dcvmn.org/>

News; Upcoming events

September 7, 2026

[Korea's EuBiologics Received WHO Prequalification for its Typhoid Conjugate Vaccine](#)

EFPIA – European Federation of Pharmaceutical Industries and Associations

<https://www.efpia.eu/news-events/>

News & Events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [12 Sep 2026]

<https://internationalbiotech.org/>

News

No new digest announcements identified.

IFPMA [12 Sep 2026]

<https://ifpma.org/>

News & Resources

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [12 Sep 2026]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [12 Sep 2026]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified....

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - Website not responding at inquiry.

CinnaGen – Iran

CinnaGen News - Website not responding at inquiry.

Clover Biopharmaceuticals – China

News

Sep 6, 2026

[Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults](#)

CSL Sequirus

News Releases - No new digest announcements identified.

Curevac

News - Website now directs to BioNTech site

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

10 September 2026

[**GSK's Shingrix \(Recombinant Zoster Vaccine\) prefilled syringe presentation approved in Japan**](#)

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases

[**HIPRA's protein-based COVID-19 vaccine available in the UK for the 2026/27 autumn vaccination programme**](#)

08-09-2026

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

News and Blog Posts - No new digest announcements identified

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Samsung Biologics

[Latest News](#) - No new digest announcements identified

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified.

Serum Institute

[News & Announcements](#) - No new digest announcements identified.

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified.

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#)

[Takeda Announces Planned Retirement of President of Research & Development Andy Plump](#)

September 10, 2026

Valneva

[Press Releases](#) - No new digest announcements identified.

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) *[No News/Announcements page identified]*

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but

indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 17 2026 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics

Sep 03, 2026 Volume 113 Issue 9 p1779-2022

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

In genomic medicine, continuously updated public archives of genetic variants linked to clinical phenotypes, such as ClinVar and the Matchmaker Exchange, are essential for variant interpretation, patient diagnosis, and treatment. This form of data sharing typically does not require explicit patient consent, especially for de-identified variant-level data, but because there are no standard data sharing guidelines, clinicians, laboratories, and patients are often left uncertain about the practical boundaries and the rationale.

Year in review

All of Us Research Program year in review: 2025

Tara Dutka, et al.

The All of Us Research Program¹ released its first genomic dataset (Curated Data Repository version 5 [CDRv5]) of almost 100,000 participants in 2022. Since then, All of Us has continued to expand the scale of its genomic offerings, releasing short-read whole genome sequencing (srWGS) for over 240,000 participants in 2023 (CDRv7) and for over 400,000 participants in 2025 (CDRv8). These genomic data are linked to a rich collection of phenotypic data encompassing electronic health records (EHRs), participant-provided information (PPI), and wearables, enabling a broad spectrum of research across diverse domains.

Articles

Examining gaps in institutional policies for clinical genomic data sharing: A cross-jurisdictional study

Zhaoping Ju, et al.

Clinical genomic data are increasingly shared for patient care, yet the rules governing sharing are often unclear. Analyzing policies from 33 institutions across 17 countries, Ju et al. find wide variation in how sharing without explicit patient consent is documented and propose baseline governance elements for more transparent, accountable practice.

American Journal of Infection Control

October 2026 Volume 54 Issue 10 p1045-1142

<http://www.ajicjournal.org/current>

Editorial

A duty to act

Emily Sickbert-Bennett, et al.;

Throughout our history, the healthcare and scientific communities have united in the face of public health crises to save lives. During natural disasters like hurricanes or wildfires, infectious diseases outbreaks and pandemics, and longstanding threats like tobacco use, robust and unified responses from healthcare professionals and scientists have delivered information, innovation, and care that has empowered millions of Americans to lead longer, healthier, and more fulfilling lives.^{1,2}

Taken together, the current spread of misinformation by federal health agencies and the dismantling of much of our public health and medical research infrastructure and healthcare safety net constitute another crisis that has already claimed American lives and is poised to do even greater damage to our nation's health. Once again, healthcare professionals and scientists have a duty to act. Our patients and communities are counting on us...

American Journal of Preventive Medicine

September 2026 Volume 71 Issue 3

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

October 2026 116(10)

<http://ajph.aphapublications.org/toc/ajph/current>

VACCINE ACCESS

Building Trust and Delivering Vaccines: The Power of Local Public Health

Bisola Ojikutu MD, MPH, Sara Black MSW, Robin Mowson MPH, MA and Lori Freeman MBA
116(10), pp. 1459–1461

AJPH as a Trusted Source for Maternal Vaccination Recommendations

Robert Kim-Farley MD, MPH, Bisola O. Ojikutu MD, MPH and Denys T. Lau PhD

AI USE IN PUBLIC HEALTH

Ethical Use of Artificial Intelligence in Public Health: Mitigating Risks and Advancing Health Equity

Terry Adirim MD, MPH and Amy Molten MD

American Journal of Tropical Medicine and Hygiene

Volume 115 (2026): Issue 2 (Aug 2026)
<https://www.ajtmh.org/view/journals/tpmd/115/2/tpmd.115.issue-2.xml>
[Reviewed earlier]

Annals of Internal Medicine

August 2026 Volume 179, Issue 8
<https://www.acpjournals.org/toc/aim/current>
[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 358 September 2026
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/358/suppl/C>
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>
(Accessed 12 Sep 2026)
[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>
(Accessed 12 Sep 2026)
[Springer-Nature site down at inquiry]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>
(Accessed 12 Sep 2026)
[Springer-Nature site down at inquiry]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>
(Accessed 12 Sep 2026)
[Springer-Nature site down at inquiry]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>
(Accessed 12 Sep 2026)
[Springer-Nature site down at inquiry]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>
(Accessed 12 Sep 2026)
[Springer-Nature site down at inquiry]

BMC Public Health

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 12 Sep 2026)

Post-campaign evaluation of the 2025 national human papillomavirus multi-age cohort vaccination campaign in Sierra Leone: a cross-sectional study of coverage, awareness and caregiver attitudes in selected districts

Samuel Adeyemi Williams, Desmond Maada Kangbai, Mamadu Baldeh

Research Open access 09 September 2026

Reentry and COVID-19: an examination of the vaccine beliefs and behaviors of Black adults in an urban community

Charles H. Lea III, Marcus D Brown, Raymond D. Adams

Research Open access 08 September 2026

Effectiveness of an on-site vaccination campaign for patients with cancer

Theresa Markus, Sarah Eitze, Sibylle C. Mellinghoff

Research Open access 07 September 2026 Article: 2540

Adult hepatitis B vaccination coverage and infection prevalence in Lagos, Nigeria: findings from a facility-based world hepatitis day study

Fehintola Anthonia Ige, Paschal Mbanefo Ezeobi, Rosemary Ajuma Audu

Research Open access 07 September 2026

Knowledge and perception regarding influenza and its vaccine among the elderly population in India: a multicentric study on the drivers of vaccine uptake

Suman Kanungo, Uttaran Bhattacharjee, Anand Krishnan

Research Open access 07 September 2026

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 12 Sep 2026)

[Springer-Nature site down at inquiry]

BMJ Evidence-Based Medicine

August 2026 - Volume 31 - 4

<https://ebm.bmj.com/content/31/4>

[Reviewed earlier]

BMJ Global Health

September 2026 - Volume 11 - 9

<https://gh.bmj.com/content/11/9>

[New issue; No digest content identified]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - July 2026

<https://thebulletin.org/magazine/2026-05/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 104, Number 8, August 2026, 525-584

<https://www.who.int/publications/journals/bulletin>

[Reviewed earlier]

Cell

Sep 03, 2026 Volume 189 Issue 18 p5479-5824

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Cell and Gene Therapy Insights

February 2026 Issue, Volume 12 Issue 1

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-1>

[Reviewed earlier]

Child Care, Health and Development

Volume 52, Issue 5 September 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 120, Issue 4 Pages: 817-1148 October 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Perspective Open Access

[Reframing the Landscape for Achieving Equitable Pharmacotherapy Health Outcomes: Introducing Pharmacogenequity](#)

Akinyemi Oni-Orisan

Pages: 840-843

First Published: 09 July 2026

Research Brief Report

[Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies](#)

Mahnum Shahzad, Magdi Elsallab, Maximilian Siebert, Florence T. Bourgeois

Pages: 930-936

First Published: 21 July 2026

Clinical Therapeutics

September 2026 Volume 48 Issue 9 p809-920

<http://www.clinicaltherapeutics.com/current>

Special Issue on "Cannabis Research and Policy: A Joint Exploration of Past and Future Therapeutic Agency - Part II"

[New issue; No digest content identified]

Clinical Trials

Volume 23 Issue 4, August 2026

<https://journals.sagepub.com/toc/CTJ/current>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 12 Sep 2026]

[Springer-Nature site down at inquiry]

Contemporary Clinical Trials

Volume 169 October 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/169/suppl/C>

Clinical Trial Management and Optimization

Research article Open access

[The promise and perils of a single IRB in multi-center clinical trials: The PEPPER trial experience](#)

Laura M. Kernan, Carol A. Lambourne, Monica Baczko-Pearl, Adina Harri, ... Vincent D. Pellegrini
Article 108445

The CRISPR Journal

Volume 9 Issue 4, August 2026

<https://journals.sagepub.com/toc/tcja/9/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 14, Issue 1 December 2026

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 42, Issue 6, 2026

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2026 - Volume 39 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

TROPICAL AND TRAVEL-ASSOCIATED DISEASES: Edited by Christina M. Coyle

[Dengue and chikungunya vaccines past, present and future: implications for travelers](#)

Francesca F. Norman, Sarah L. McGuinness, Lin H. Chen

GASTROINTESTINAL INFECTIONS: Edited by Priscilla Rupali

[Recent developments in typhoidal and non-typhoidal *Salmonella* vaccines](#)

Michael Blank, Anna Rydlova, Malick M. Gibani

PAEDIATRIC AND NEONATAL INFECTIONS: Edited by M. Asunción Mejías

The return of measles: a dangerous comeback

Katia C. Halabi

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 12 Sep 2026]

[No new digest content identified]

Cytotherapy

September 2026 Volume 28 Issue 9

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 26, Issue 2 Pages: 81-130 June 2026

<https://onlinelibrary.wiley.com/toc/14718847/current>

Special Issue: Military Global Health Engagements

[Reviewed earlier]

Development in Practice

Volume 36, 2026 Issue 4

<https://www.tandfonline.com/toc/cdip20/36/4?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 44, Issue 5 September 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 20 - 2026

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 50, Issue 4 October 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 130 August 2026

<https://www.sciencedirect.com/journal/ebiomedicine/vol/130/suppl/C>

[Reviewed earlier]

EMBO Reports

Volume 27, Issue 17 September 2026

<https://link.springer.com/journal/44319/volumes-and-issues/27-17>

[New issue; No digest content identified]

Emerging Infectious Diseases

Volume 32, Number 9—September 2026

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 56 September 2026

<https://www.sciencedirect.com/journal/epidemics/vol/56/suppl/C>

Review article Open access

[Mapping the landscape of individual-based models for respiratory pathogen transmission in the pandemic and post-pandemic era \(2020–2024\): A systematic review](#)

Shreeya Mhade, Utkarsh Bhosekar, Megan D. Hill, Shelly Sinclair, ... Marco Ajelli

Article 100924

Research article Open access

[Clinical impact of childhood and adolescence dengue vaccination in Indonesia: A dynamic transmission modeling study](#)

Salisu M. Garba, Ibrahim Diakite, Yao-Hsuan Chen, John C. Lang, ... Elamin Elbasha

Article 100932

Epidemiology and Infection

Volume 154 - 2026

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 48, Issue 4 Pages: 1-45 July–August 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

Organ-on-a-chip technology :: Consent and decisional incapacity

[Reviewed earlier]

Ethics & International Affairs

Volume 40 - Issue 1 - Spring 2026

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/33/suppl/Cc>
[Reviewed earlier]

The European Journal of Public Health

Volume 36, Issue 3, June 2026

<https://academic.oup.com/eurpub/issue/36/3>

[Reviewed earlier]

Expert Review of Vaccines

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

September/October 2026 Volume 105, Number 5

<https://www.foreignaffairs.com/issues/2026/105/5>

[Reviewed earlier]

Forum for Development Studies

Volume 53, 2026 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 12 Sep 2026]

Review

Published on 10 Sep 2026

[The European Health Data Space and biobanking in Europe: synergies, tensions and the future governance of data-driven health research](#)

Laura Grech, Nikolai Paul Pace

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 12 Sep 2026]

Review Published on 10 Sep 2026

[Advancements in CRISPR-based in vivo gene therapy for hemophilia](#)

Xiaoyu Zhang, et al.

Review Published on 10 Sep 2026

[Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders](#)

Khushi Bashir, et al.

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1657>

Accessed 12 Sep 2026]

Editorial

Published on 11 Sep 2026

[Editorial: Enhancing the health of vulnerable populations through integrated biosocial approaches](#)

Echu Liu, et al.

Editorial

Accepted on 08 Sep 2026

[Editorial: " Paediatric drug development"](#)

Mette Due Theilade Thomsen, et al.

Review

Accepted on 04 Sep 2026

[Vaccination of patients with hematological malignancies: barriers and strategies to improve uptake](#)

Toni Valković, et al.

Gene Therapy – Nature

Volume 33 Issue 4, July 2026

<https://www.nature.com/gt/volumes/33/issues/4>

[Springer-Nature site down at inquiry]

Genetics in Medicines

Volume 28, Issue 8 August 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/8>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 12 Sep 2026]

[Springer-Nature site down at inquiry]

Global Health Action

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2026

<https://pmc.ncbi.nlm.nih.gov/search/?term=%22Glob%20Health%20Sci%20Pract%22%5Bjournal%5D>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc
[Accessed 12 Sep 2026]
[No new digest content identified]

Global Public Health

Volume 21, Issue 1 (2026)
<http://www.tandfonline.com/toc/rgph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 12 Sep 2026]
[Springer-Nature site down at inquiry]

Health and Human Rights

Volume 28, Issue 2, June 2026
<https://www.hhrjournal.org/volume-28-issue-1-june-2026/>
Special Section: Children's Right to Health
[Reviewed earlier]

Health Economics, Policy and Law

Volume 21 - Issue 3 - July 2026
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 41, Issue 7, August 2026
<https://academic.oup.com/heapol/issue/41/7>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 12 Sep 2026]
[Springer-Nature site down at inquiry]

Human Gene Therapy

Volume 37 Issue 15-16, August 2026
<https://journals.sagepub.com/toc/hgta/37/15-16>
Editorial

[**The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach**](#)

Christian Gallu

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 12 Sep 2026]

[No new digest content identified]

Immunity

Sep 08, 2026 Volume 59 Issue 9 p2351-2600

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 12 Sep 2026]

[Springer-Nature site down at inquiry]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

Latest articles

[Springer-Nature sites down at inquiry]

International Health

Volume 18, Issue 5, September 2026

<https://academic.oup.com/inthealth/issue/18/5>

Editorial

[Women's right to science and health: 30 years on, progress and gaps remain](#)

Sandrine Hakiza and Silvia Ferazzi

Original Articles

[Coverage and determinants of hepatitis B virus vaccine uptake among children aged 12–36 months in Ethiopia: an analysis of the 2016 Ethiopian Demographic and Health Survey](#)

Kathleen Kenyatta White and others

International Human Rights Law Review

Volume 15 (2026): Issue 1 (Jun 2026)

<https://brill.com/view/journals/hrlr/hrlr-overview.xml>

[Reviewed earlier]

The International Journal of Children's Rights

Volume 34 (2026): Issue 2 (Jun 2026)

<https://brill.com/view/journals/chil/34/2/chil.34.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 13 No. 8 (2026): August 2026

<https://www.ijcmph.com/index.php/ijcmph/issue/view/139>

Articles

[New issue; No digest content identified]

International Journal of Epidemiology

Volume 55, Issue 3, June 2026

<https://academic.oup.com/ije/issue/55/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 19, Issue 2 22 April 2026

<https://www.emerald.com/ijhrh/issue/19/2>

[Reviewed earlier]

JAMA

September 8, 2026, Vol 336, No. 10, Pages 815-**900**

<https://jamanetwork.com/journals/jama/currentissue>

AI in Medicine - Multimedia

Enriching Clinical Trials With Machine Learning

Roy Perlis, MD, MSc

Viewpoint

Imminent Threats to the US Preventive Services Task Force

John B. Wong, MD; Esa M. Davis, MD, MPH; Michael Silverstein, MD, MPH

JAMA. 2026;336(10):825-826. doi:10.1001/jama.2026.14814

This Viewpoint discusses how leadership and structural changes at the US Preventive Services Task Force could affect clinicians' access to evidence-based recommendations and therefore the health of US patients.

Dismantling Independent Science—The Supreme Court and Public Health Regulation

Lawrence O. Gostin, JD; Peter Lurie, MD, MPH

JAMA. 2026;336(10):827-828. doi:10.1001/jama.2026.15473

This Viewpoint summarizes the ways in which federal health agencies and state-level safeguards work in parallel to ensure public health and highlights how 3 recent Supreme Court rulings have reduced the independence of federal agencies, expanded political control over them, and curtailed state-level protections meant to challenge and supplement federal standards.

JAMA Health Forum

September 2026, Vol 7, No. 9

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

September 2026, Vol 180, No. 9, Pages 923-1051

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Viewpoint

Making Vaccine Policy Values and Trade-Offs Transparent—Rebuilding a Consensus Supporting Immunization

Edgar K. Marcuse, MD, MPH; Gregory A. Poland, MD

JAMA Pediatr. 2026;180(9):925-926. doi:10.1001/jamapediatrics.2026.2831

Traditionally, scientific evidence of vaccine safety, efficacy, and programmatic feasibility have been the foundation of US vaccine policymaking. These components are no longer sufficient because vaccine policy debates now focus on perceived conflicts between individual autonomy and societal benefit. Today, science-based vaccination policy has been replaced by a politically based policymaking accompanied by unprecedented acrimony that inhibits civil discussion of policy options. To address this debacle, we propose restoring the science-based policymaking and adding a new component: a transparent process for explicitly identifying and weighing the inherent values and trade-offs.

JBI Evidence Synthesis

August 2026 - Volume 24 - Issue 8

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

September 2026 Volume 79 Issue 3 p293-450

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 85 (2026)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 51, Issue 4 August 2026

<https://link.springer.com/journal/10900/volumes-and-issues/51-4>

[Springer-Nature sites down at inquiry]

Journal of Development Economics

Volume 183 September 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/183/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 21 Issue 4, October 2026

<http://journals.sagepub.com/toc/jre/current>

Empirical Studies of Stakeholder Perspectives on Selected Issues in Research Ethics

Open Access Research article First published June 3, 2026pp. 253–274

Attitudes of Longitudinal Study Participants and Members of the Public Towards Data Sharing for Secondary Research: A Survey Based Approach

Nicola Howe

Open Access Research article First published May 15, 2026pp. 284–298

Ethical Challenges Posed by HIV-Vaccine Induced Seropositivity for the Informed Consent Process and HIV Testing Practices in Maputo City, Mozambique

Emilia Fumane

Journal of Epidemiology & Community Health

June 2026 - Volume 80 - 6

<https://jech.bmj.com/content/80/6>

[Reviewed earlier]

Journal of Evidence-Based Medicine

September 2026 - Volume 80 - 9

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

Journal of Global Ethics

Volume 22, Issue 1 (2026)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 37, Number 3, August 2026

<https://muse.jhu.edu/issue/56931>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 28, Issue 4 August 2026

<https://link.springer.com/journal/10903/volumes-and-issues/28-4>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 24, Issue 3 (2026)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 38, Issue 6 Pages: 933-1093 August 2026

<https://onlinelibrary.wiley.com/toc/10991328/current>

RESEARCH ARTICLE

Navigating Metrics: Disparities and Challenges in Project Evaluations Across Global Development Organisations

Bryan Cook, Elizabeth Jackson, Paul Alexander

Pages: 989-998

First Published: 07 July 2026

Journal of Law, Medicine & Ethics

Volume 54 - Supplement S2 - Summer 2026

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

Supported Decision-Making in Clinical Research

[Reviewed earlier]

Journal of Medical Ethics

August 2026 - Volume 52 - 8

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 13, Issue 2 (2026)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 296 September 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/296/suppl/C>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

Volume 19, 2026 Issue 1

<https://www.tandfonline.com/toc/jppp20/19/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2026 - Volume 32 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 47, Issue 3 September 2026

<https://link.springer.com/journal/41271/volumes-and-issues/47-3>

[New issue; No digest content identified]

Journal of the Royal Society – Interface

Volume 23, Issue 242 1 September 2026

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 33, Issue 5, July 2026
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

The Lancet

Sep 12, 2026 Volume 408 Number 10559 p969-1060
<https://www.thelancet.com/journals/lancet/issue/current>
Editorial

Gene-editing therapies: delivering safely for patients

The Lancet

Comment

Offline: The tragic fallacy of global health reform

Richard Horton

...The objective of constructing an orderly new global health architecture, as if those leading this reform process are drawing their glittering new structure on a perfectly blank page, ignores the long-standing competitiveness and enmity between existing institutions that, once born, make it their overriding priority to live on indefinitely. Self-preservation is only part of the reason why reforms will stall and wither. There are too many vested interests among those who would prefer the status quo to continue. And, anyway, what of other regions of the world? Where are the diverse voices from Latin America? Or Asia? Or the Middle East? Where are civil society organisations? Would countries and their peoples even trust a new architecture once it was built? What is sometimes forgotten is that global health is about power—and the rich world, despite its kindly reassurances, will not loosen the ties that keep countries constrained and dependent. And remember: reform has been a subject for rumination ever since global health entered our lexicon. Are we not tired of the brooding vanity that informs so many of these discussions? Borges concluded his story this way: "A scattered dynasty of solitary men has changed the face of the world. Their task continues." The task of global health reform will undoubtedly continue, motivated by illusions of order and symmetry. Councils, panels, and task forces will thrive and reproduce. And this vast displacement activity will likely contribute not one trace of benefit to the health of peoples.

Articles

Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study

Megan Halbrook, et al

... Background

There are currently no licensed vaccines for disease caused by Bundibugyo virus (BDBV). The recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein (rVSVΔG-ZEBOV-GP) vaccine has been widely deployed during Ebola virus disease outbreaks caused by Ebola virus (EBOV). Human studies have shown cross-reactive BDBV antibody responses following licensed Ebola virus disease vaccine administration, but the durability and longitudinal kinetics of these responses in populations vaccinated during outbreaks remain unknown. We aimed to evaluate BDBV glycoprotein seroreactivity following rVSVΔG-ZEBOV-GP vaccination in two longitudinal cohorts from regions of the Democratic Republic of the Congo affected by Ebola virus disease outbreaks.

The Lancet Child & Adolescent Health

Oct 2026 Volume 10 Number 10 p687-776, e30
<https://www.thelancet.com/journals/lanchi/issue/current>
Comment

Rotavirus vaccine success and the challenge of vaccine equity

Daniel Hungerford, Latif Ndeketa

Since 2006, rotavirus vaccination for infants has transformed the global burden of childhood diarrhoeal disease, preventing millions of hospitalisations and an estimated 140 000 deaths between 2006 and 2019.^{1,2} Yet, despite more than 140 countries including rotavirus vaccines in their routine immunisation schedule, data from the International Vaccine Access Center estimate that around 70 million infants remained unprotected in 2024, and rotavirus still accounts for approximately 40% of diarrhoeal deaths in children younger than 5 years globally.¹

Comment

Unleash the synergies: children's rights and the new strategy for child and adolescent health in Europe and Central Asia

Andrew Clarke, et al.

More than three decades after the adoption of the UN Convention on the Rights of the Child, fulfilment of child rights within health systems worldwide remains uneven and poorly operationalised. Many children continue to face preventable barriers to safe, responsive, and rights-respecting care, reflecting persistent health-system failures in delivering equitable, high-quality services and resulting in avoidable suffering. Examples include, but are not limited to, separation of children from parents, denial of confidentiality for adolescents, lack of child participation in decisions about their health, poor pain management, over-medicalisation of care, and prolonged hospitalisation.¹

Articles

Rotavirus vaccine effectiveness against rotavirus and acute gastroenteritis mortality: an analysis of pooled case–control studies from the MNSSTER-V dataset

Mary C Moran, et al. on behalf of the Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V) project working group

Health Policy

Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children

Tiziana Masini, et al. on behalf of the PADO-SCD participants

Lancet Digital Health

Aug 2026 Volume 8 Number 8

<https://www.thelancet.com/journals/landig/issue/current>

Comment

Ethics oversight of health-related research should be contemporaneous in the age of artificial intelligence

Rohit Malpani, Keymanthri Moodley, Maria Magdalena Guraiib, Antonella Lavelanet, Andreas Reis ... Over an 18-month period, the WHO Expert Group on Ethics and Governance of AI for health deliberated on these diverse challenges, culminating in a new report—*Artificial Intelligence-related Health Research: ethics review and oversight*—released in July, 2026.¹ The Expert Group considered three categories of AI-related health research: (1) research that uses AI-based technologies to collect or analyse large data sets, including those from social media, for any social science, biomedical, clinical, behavioural, or epidemiological activity aimed at generating new knowledge for a health-related purpose; (2) research that uses AI-based research tools to conduct research, such as synthetic data; and (3) research that evaluates the utility, safety, efficacy, and implementation of AI-based health applications and tools used on patients or to influence patient behaviour.

Lancet Global Health

Sep 2026 Volume 14 Number 9
<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Sep 2026 Volume 26 Number 9 p871-974, e321-e385
<https://www.thelancet.com/journals/laninf/issue/current>
Comment

[Beyond vaccines: closing the critical gap in diagnostics and therapeutics for outbreak response](#)

Tedros Adhanom Ghebreyesus, Jean Kaseya, Chikwe Ihekweazu, Vasee Moorthy, Mosoka Fallah, Shanelle Hall, Sylvie Briand

Comment

[Reconsidering the rVSVAG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak](#) Krutika Kuppalli, et al.

Lancet Public Health

Sep 2026 Volume 11 Number 9 e583-e726
<https://www.thelancet.com/journals/lanpub/issue/current>
[New issue; No digest content identified]

Lancet Respiratory Medicine

Sep 2026 Volume 14 Number 9 p747-836, e57
<https://www.thelancet.com/journals/lanres/issue/current>
[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 30, Issue 8 August 2026
<https://link.springer.com/journal/10995/volumes-and-issues/30-8>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 46 Issue 6, August 2026
<https://journals.sagepub.com/toc/MDM/current>
[Reviewed earlier]

Medical Law International

Volume 26 Issue 3, September 2026
<https://journals.sagepub.com/toc/MLI/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 104, Issue 2 Pages: 293-580 June 2026

<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Sep 02, 2026 Volume 34 Issue 9 p5021-5612
<https://www.cell.com/molecular-therapy/current>
[New issue; No digest content identified]

Nature

Volume 657 Issue 8131, 10 September 2026
<https://www.nature.com/nature/volumes/655/issues/8131>
Editorial 08 Sept 2026

[The World Bank is right to prioritize reproducibility](#)

The development bank and others are starting to publish and verify the raw data and code accompanying their research-based reports and papers. Other agencies should do the same.

Article Open Access 29 Jul 2026

[The past and future impact of climate change on childhood malaria in Africa](#)

Climate and econometric modelling reveal that human-induced climate change is shifting the burden of childhood malaria in Africa.

Colin J. Carlson, Tamma Carleton, Christopher H. Trisos

Nature Biotechnology

Volume 44 Issue 9, September 2026
<https://www.nature.com/nbt/volumes/44/issues/7>
[New issue; No digest content identified]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 12 Sep 2026)
[Reviewed earlier]

Nature Genetics

Volume 58 Issue 9, September 2026
<https://www.nature.com/ng/volumes/58/issues/9>
Comment 10 Jul 2026

[A call to action for an equitable global genomic system](#)

As genomics infrastructure expands, current governance will determine whether it advances global health equity or entrenches disparities, locking biased data into future clinical tools. This Comment calls for inclusive, community-centered genomic systems, before biased data and extractive models becoming the default.

Deborah Mascalcioni, Sara Niedbalski, Ahmad Abou Tayoun

Nature Human Behaviour

Volume 10 Issue 8, August 2026
<https://www.nature.com/nathumbehav/volumes/10/issues/8>

[New issue; No digest content identified]

Nature Medicine

Volume 32 Issue 8, August 2026

<https://www.nature.com/nm/volumes/32/issues/8>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 25 Issue 9, September 2026

<https://www.nature.com/nrd/volumes/25/issues/9>

Comment 06 May 2026

[Bridging boundaries: making drug repurposing the new normal](#)

The potential for drug repurposing to provide faster, cost-effective ways to address unmet medical needs remains to be fully realized. Overcoming systemic challenges and promoting collaboration will be key for drug repurposing to contribute more to new treatments, especially for rare diseases.

Jake Fairnie, Sarai Rodríguez-Navarro, Donald C. Lo

Nature Reviews Genetics

Volume 27 Issue 9, September 2026

<https://www.nature.com/nrg/volumes/27/issues/9>

[New issue; No digest content identified]

Nature Reviews Immunology

Volume 26 Issue 9, September 2026

<https://www.nature.com/nri/volumes/26/issues/9>

[New issue; No digest content identified]

New England Journal of Medicine

Volume 395 No. 10 September 10, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

[The Future of the USPSTF and Evidence-Based Recommendations](#)

E. Kaplan and C. Shachar

Abstract

In May 2026, two members of the U.S. Preventive Services Task Force were fired. Vigilance will be necessary to ensure that the panel continues to adhere to rigorous scientific methods.

NEJM Evidence

Volume 5 No. 9 September 2026

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>
[Accessed 12 Sep 2026]
[No new digest content identified]

Pediatrics

Volume 158, Issue 3 September 2026
<https://publications.aap.org/pediatrics/issue/158/2>
Research

Effectiveness of RSV Prevention Strategies in US Infants: 2024–2025

Amanda B. Payne, PhD; Steph Battan-Wraith, PhD; Sarah E. Reese, PhD; Cassandra A. Hathaway, PhD; Sara Y. Tartof, PhD ...

State-of-the-Art Reviews

What's Old Is New Again: Varicella

Caitlin Naureckas Li, MD, MHQS; Kathryn M. Edwards, MD; Sheldon L. Kaplan, MD; Gary S. Marshall, MD; Sarah Parker, MD ...

From the American Academy of Pediatrics

Policy Statement

Reception and Assessment of Immigrant Children and Families Seeking US Humanitarian Protection: Upholding the Best Interest of the Child: Policy Statement

J. Raul Gutierrez, MD, FAAP; Sural Shah, MD, FAAP; Julie M. Linton, MD, FAAP; Alan Shapiro, MD, FAAP; Council on Immigrant Child and Family Health

PharmacoEconomics

Volume 44, Issue 9 September 2026
<https://link.springer.com/journal/40273/volumes-and-issues/44-9>
[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 12 Sep 2026)
[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>
(Accessed 12 Sep 2026)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 12 Sep 2026)

Assessing the impact of a gender-neutral approach to HPV vaccination on vaccination coverage for nine-year-old girls in Cameroon: A retrospective, cross-sectional study

Bridget C. Griffith, Shariffatou Iliassu, Clarence Mbanga, Budzi Michael Ngege, Sonali Patel, Justin C. Graves, Navpreet Singh, Shalom Ndoula, Andreas Ateke Njoh, Efouba Gisele, Shadrack Mngemane, Tosin Ajayi, Laure-Anais Zultak, Yauba Saidu
Research Article | published 09 Sep 2026 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0006349>

[Religious beliefs and practices, political orientation, and distrust in healthcare predict attitudes toward mRNA vaccines in the United States](#)

Erin D. Solomon, Eu Gene Chin, Kari Baldwin, Lauren L. Baker, James M. DuBois
Research Article | published 09 Sep 2026 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0006330>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>
(Accessed 12 Sep 2026)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>
(Accessed 12 Sep 2026)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>
[Accessed 12 Sep 2026]
[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 12 Sep 2026]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

September 8, 2026 vol. 123 no. 36
<https://www.pnas.org/toc/pnas/123/36>
[New issue; No digest content identified]

PNAS Nexus

Volume 5, Issue 8, August 2026
<https://academic.oup.com/pnasnexus/issue/5/8>
[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 41 - Issue 1 - 2026
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 210 September 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/210/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

Volume 293, Issue 2077 August 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 257 August 2026

<https://www.sciencedirect.com/journal/public-health/vol/257/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2026, Vol. 29, No. 1

<https://karger.com/phg/issue/29/1>

[Reviewed earlier]

Public Health Reports

Volume 141 Issue 3, May/June 2026

<https://journals.sagepub.com/toc/phrg/141/3>

[Reviewed earlier]

Qualitative Health Research

Volume 36 Issue 9, August 2026

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 22 Issue 3, July 2026

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 12 Sep 2026]
[Springer-Nature site down at inquiry]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>
Latest Articles
[No new digest content identified]

Risk Analysis

Volume 46, Issue 9 September 2026
<https://onlinelibrary.wiley.com/toc/15396924/current>
[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>
[Accessed 12 Sep 2026]
[No new digest content identified]

Royal Society Open Science

Volume 13, Issue 8 1 August 2026
<https://royalsocietypublishing.org/toc/rsos/current>
[Reviewed earlier]

Science

Volume 393| Issue 6816| 10 Sep 2026
<https://www.science.org/toc/science/current>
Editorial

[China's ultimate orchestration—integrating the science](#)

BY Dan Wang
10 Sep 2026

As China has matured into a technological and manufacturing superpower, the United States and Europe have managed to retain leadership in some of the most scientifically intensive industries, such as semiconductors and aviation. But that advantage too is at risk. China has grown into a near-peer to the United States in many scientific disciplines and will make deeper inroads into these industries as well. The United States government needs to stop beating up on its scientists, or it will cede one of its great strengths—the development of technologies that require the complex integration of varied scientific disciplines...

Science and Engineering Ethics

Volume 32, Issue 5 October 2026
<https://link.springer.com/journal/11948/volumes-and-issues/32-5>
[New issue; No digest content identified]

Science Translational Medicine

Volume 18| Issue 866| 9 Sep 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 12 Sep 2026]

[No new digest content identified]

Social Science & Medicine

Volume 405 September 2026

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/405/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 12 Sep 2026]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 47, Issue 4 August 2026

<https://link.springer.com/journal/11017/volumes-and-issues/47-4>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 72 July–August 2026

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/72/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 31, Issue 9 Pages: 1137-1290 September 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 91 3 October 2026

<https://www.sciencedirect.com/journal/vaccine/vol/91/suppl/C>

Discussion No access

[**Mandates or “Medical Freedom”? What Florida parents' attitudes suggest about the future of childhood vaccination**](#)

Amelia M. Jamison, Samee Saiyed, Lauren M. Gardner

Article 129060

Discussion No access

[Measles resurgence in Indonesia: the intersection of immunity gaps, subnational heterogeneity, and vaccine confidence](#)

Timotius Ivan Hariyanto
Article 129085

Discussion No access

[Ethical considerations of incentive structures in vaccine acceptance research](#)

Mohamed Amer Musrati, Salem S

Short communication Abstract only

[Lessons learnt from one-year cold chain support for COVID-19 vaccination in 5 middle income countries of North Africa](#)

Srihari Dutta, Daniel Ngemera, Philippe Jaillard, Sumeet Juneja
Article 128994

Short communication Abstract only

[Elevating immunization as a political and economic priority in Africa: Reflections from the continental consensus on Africa's continental immunization strategy in november 2025 in Kigali, Rwanda](#)

Antoinette Eleonore Ba, Fidele Ngabo, Charles Shey Wiysonge, Chris Ngwa Akonwi, ... Landry Tsague
Article 129042

Research article Open access

[Quantifying the cost of measles outbreaks in the U.S. and how costs scale with outbreak size](#)

Salin Sriudomporn, Bryan Patenaude
Article 129040

Research article Open access

[Human papillomavirus \(HPV\) Vaccination programmes across European countries: time-harmonized coverage among adolescent females, socioeconomic predictors, and impact on public interest](#)

Grazia Pavia, Angela Quirino, Nadia Marascio, Francesca Licata, ... Gianfranco Di Gennaro
Article 129058

Research article Open access

[Scaling up vaccination for people living in prisons: a global person-centred need for public health](#)

Esergita Thanasi, Joseph McGregor-Harper, Maria Paola Tramonti Fantozzi, Nicola Cocco, ... Lara Tavoschi
Article 129039

Research article Open access

[Measles outbreak risk in Afghanistan: provincial immunity gaps and epidemic potential following immunisation system disruption](#)

Rajeev Ranjan, Palwasha Anwari, Abigail Colson, Robert van der Meer
Article 129078

Vaccines

<https://www.mdpi.com/journal/vaccines>
[Accessed 12 Sep 2026]

Open Access Article

Understanding COVID-19 Vaccination Intention in Japan: The Influence of Individual Social Capital and Personal Beliefs on Vaccination

by Yutaro Furukawa, Mikiko Tokiya, Takaomi Kobayashi, Xueyan Zhang and Megumi Hara
Vaccines 2026, 14(9), 795; <https://doi.org/10.3390/vaccines14090795> - 9 Sep 2026

Abstract

Background/Objectives: Vaccine hesitancy remains a significant public health challenge in Japan, particularly following the HPV vaccine suspension (2013–2022) that severely damaged vaccination trust. Although prior studies have linked individual social capital to vaccination behavior in Japan, whether and how personal vaccination beliefs [...]

Open Access Article

From Information to Vaccination: A Conceptual Framework for Understanding Community Participation in Catch-Up Vaccination for Children in Abidjan, Côte d'Ivoire

by Abdoul Gadiry Fadiga, ASM Shahabuddin, Kevin Sylvestre Yohou, Françoise Soro, Mathilde Manouan, Bognan Valentin Kone, Tania N'zi-Boa, Josette Dedoh, Akissi Régine Attia-Konan and Julie Sackou-Kouakou
Vaccines 2026, 14(9), 786; <https://doi.org/10.3390/vaccines14090786> - 8 Sep 2026

Abstract

Background/Objectives: Catch-up vaccination is essential for reaching zero-dose and under-vaccinated children. However, community participation depends on several factors whose interactions remain insufficiently understood. This study aimed to analyze the dimensions structuring community participation in catch-up vaccination and to develop a conceptual framework [...]

Value in Health

September 2026 Volume 29 Issue 9 p1539-1748
<https://www.valueinhealthjournal.com/current>
[New issue; No digest content identified]

World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71
<https://www.wma.net/publications/world-medical-journal/>
[Reviewed earlier]

World Development

Volume 205 September 2026
<https://www.sciencedirect.com/journal/world-development/vol/205/suppl/C>
[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)
:: [*WHO*](#)
:: [*Organization Announcements*](#)
:: [*Journal Watch*](#)
:: [*Pre-Print Servers*](#)

.....

.....

Pre-Print Servers

arXiv

<https://arxiv.org/>

[Accessed 12 Sep 2026]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

No new digest content identified.

New - bioRxiv

<https://www.biorxiv.org/content/early/recent>

[Accessed 12 Sep 2026]

[Filters: Bioengineering, Evolutionary Biology, Genetics, Genomics, Neuroscience, Synthetic Biology]
Website not fully responding at inquiry...timing out from sequential citation exploration...exploring workaround options]

No new digest content identified.

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 12 Sep 2026]

[Filter: All articles]

Website not fully responding at inquiry...timing out from sequential citation exploration...exploring workaround options]

No new digest content identified.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 12 Sep 2026]

[Filter: All articles]

No new digest content identified.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

No new digest content identified.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 12 Sep 2026]

Research ArticleOpen Access

[REVISED - Evaluating the 7-1-7 Outbreak Response Metric: Modelling and Implementation Insights for Ebola, Measles, and Anthrax in Central and Eastern Uganda, 2025](#)

[version 2; peer review: 2 approved with reservations]

Abel W. Walekhwa. Et al.

Abstract

Introduction

Uganda's recent progress in public health emergency preparedness underscores the relevance of the 7-1-7 framework (detection within 7 days, notification within 1 day, response within 7 days). Evidence on the incremental benefits of meeting these targets in resource-constrained settings remains limited. We modelled cases averted and cost-effectiveness of achieving 7-1-7 timelines for Sudan virus disease (SVD), measles, and anthrax in Uganda, and additionally explored more ambitious targets (3-1-4 and 1-1-1).

* * * *

Think Tanks

Brookings [to 12 Sep 2026]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

Center for Global Development [12 Sep 2026]

<https://www.cgdev.org/>

All Research

No new digest content identified.

Chatham House [to 12 Sep 2026]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [12 Sep 2026]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 12 Sep 2026]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

IS Global [to 12 Sep 2026]

<https://www.isglobal.org/en/press>

Press releases

[Taxing Billionaires and Redistributing Wealth Could Save Millions of Lives Amid Global Aid Cuts](#)

08.09.2026

An ISGlobal-led study estimates that international tax and redistribution measures could generate enough resources to substantially improve health outcomes in low-income countries, helping offset the effects of declining development assistance.

McKinsey Global Institute [to 12 Sep 2026]

<https://www.mckinsey.com/mgi/overview>

Featured Research

[The AI economy: Interconnected forces, feedback loops, and speeds of change](#)

September 10, 2026 -

AI is shaped by forces far beyond the technology itself, and its effects reach just as widely. Mapping how the pieces interact helps us see what could influence its course and where hurdles and opportunities may emerge.

ODI [Overseas Development Institute] [to 12 Sep 2026]

<https://odi.org/en/publications/>

Publications

No new digest content identified.

Pew Research Center [to 12 Sep 2026]

<https://www.pewresearch.org/>

Latest Publications

No new digest content identified.

Rand [to 12 Sep 2026]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 12 Sep 2026]

<https://www.urban.org/research>

New Research Publications - Selected

No new digest content identified.

World Economic Forum [to 12 Sep 2026]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....
.....

Public Consultations/Calls for Inputs/Calls for Papers

Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making

A Notice by the Health and Human Services Department on 08/24/2026, **Comment period ends 09/20/2026.**

SUMMARY:

The Department of Health and Human Services (HHS or the Department), in support of the Task Force on Safer Childhood Vaccines and in furtherance of the Executive Order of August 10, 2026, "Delivering Gold Standard Childhood Vaccine Recommendations for Americans," seeks public comment on whether the categories currently used in Federal vaccine recommendations are adequate. Those categories are routine (universal) recommendations, risk-based recommendations, and recommendations based on shared clinical decision-making, also referred to as individual-based decision-making. The Department seeks comment on these categories and whether additional or different categories should be adopted. The Department further seeks comment on the considerations that should be relied upon in setting vaccine recommendations, including the availability and strength of available scientific evidence, the appropriate approach when randomized controlled trial evidence is limited or absent, a presumption in favor of individual autonomy and religious freedom, the downstream legal and programmatic consequences of category assignment, and the communication practices necessary to earn and maintain public trust.

WMA - Declaration of Taipei Revision Launched [Ongoing]

...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.

In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.

Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...

In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

* * * *

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2026. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*